TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9022575

Group type: EXPERIMENTAL
Intervention: Dynamic MR imaging
Number of subjects: 40

Group type: COMPARATOR
Intervention: T2-weighted images
Number of subjects: 40

Group type: COMPARATOR
Intervention: Contrast-enhanced T1-weighted images
Number of subjects: 40
Study: 8198932

Group type: EXPERIMENTAL
Intervention: [S]-leucovorin (300 mg m-2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: rac-leucovorin (600 mg m-2)
Number of subjects: 21
Study: 2822879

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol and 10 mg enalapril (low-dose combination)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (during 2-week placebo period)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Atenolol vs Enalapril
Number of subjects: 26
Study: 29299736

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no probiotic supplementation)
Number of subjects: 15
Study: 29862395

Group type: EXPERIMENTAL
Intervention: Dietary supplement based on Lippia citriodora and Hibiscus sabdariffa polyphenolic extracts
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26257041

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS) system implantation, first implant (n=22)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS) system implantation, fifth implant (n=10)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS) system implantation
Number of subjects: 126
Study: 24184147

Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) in adults (n=54)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) in children (n=99)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) in adults
Number of subjects: 153
Study: 23155007

Group type: EXPERIMENTAL
Intervention: W→G
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: R→B
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: G→B
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: B→G
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: W→B
Number of subjects: 512
Study: 21058611

Group type: EXPERIMENTAL
Intervention: Dual Process Model (DPM) intervention with both loss-orientation (LO) and restoration-orientation (RO) coping
Number of subjects: 298

Group type: COMPARATOR
Intervention: Traditional grief groups focusing on loss-orientation (LO)
Number of subjects: 298
Study: 17983336

Group type: EXPERIMENTAL
Intervention: Acupuncture + Relaxation Response (RR)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (Acupuncture + Soft Music)
Number of subjects: 119
Study: 14979891

Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (10 subjects)
Number of subjects: 10
Study: 11121919

Group type: EXPERIMENTAL
Intervention: Oral menadiol 20 mg o.d. for 3 days (n=12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous phytomenadione 10 mg o.d. for 3 days (n=14)
Number of subjects: 26
Study: 9125681

Group type: EXPERIMENTAL
Intervention: Lacidipine, 4 mg daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1607091

Group type: EXPERIMENTAL
Intervention: Oral lavage plus enemas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral lavage alone
Number of subjects: 0
Study: 2984617

Group type: EXPERIMENTAL
Intervention: Neo Sampoon tablets
Number of subjects: 450

Group type: COMPARATOR
Intervention: Collatex sponge
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 450
Study: 3689613

Group type: EXPERIMENTAL
Intervention: i.v. cimetidine 200 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: i.v. ranitidine 50 mg
Number of subjects: 20
Study: 31058387

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Statin therapy in septic patients
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Continuation of statins
Number of subjects: 1462
Study: 28620941

Group type: EXPERIMENTAL
Intervention: 3 × 75 g sucrose per day for 14 days
Number of subjects: 12
Study: 23786500

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention through hospital pharmacists
Number of subjects: 385

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 385
Study: 22981342

Group type: EXPERIMENTAL
Intervention: 5-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by 625 mg orally every 8h for 4 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously every 8h for 24h, followed by placebo orally at the same time intervals
Number of subjects: 62
Study: 21544000

Group type: EXPERIMENTAL
Intervention: General + Specific Warm-Up (G + SWU)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Specific Warm-Up (SWU)
Number of subjects: 13
Study: 18434903

Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.1 microg/kg/min started at surgical induction and continued for 48 hrs
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg orally twice a day, from preoperative day 1 to postoperative day 1
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both fenoldopam and N-acetylcysteine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 79
Study: 17060807

Group type: EXPERIMENTAL
Intervention: ECG with the position of electrodes marked on the skin using a dermographic pen
Number of subjects: 276

Group type: COMPARATOR
Intervention: Traditional ECG without marking the position of electrodes
Number of subjects: 276
Study: 15138096

Group type: EXPERIMENTAL
Intervention: Isolated aortic valve replacement with 23‐mm St. Jude Medical prosthetic valves and posterior aortic root enlargement
Number of subjects: 19

Group type: COMPARATOR
Intervention: 19‐mm and 21‐mm St. Jude Medical prosthetic valves implanted without aortic root enlargement
Number of subjects: 19
Study: 11075310

Group type: EXPERIMENTAL
Intervention: RGD891 (60 micrograms/kg bolus dose + 336 micrograms/kg 8-h infusion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RGD891 (various intravenous regimens)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RGD891
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RGD039
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RGD891 and RGD039
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RGD891 with PPACK
Number of subjects: 2
Study: 9146820

Group type: EXPERIMENTAL
Intervention: 0.2 mg buprenorphine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.1 mg naloxone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.2 mg buprenorphine and 0.1 mg naloxone in combination
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8398324

Group type: EXPERIMENTAL
Intervention: STADMAX (scopolamine, tavegyl, ativan, dexamethasone, high dose maxolon)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: STADMAX
Number of subjects: 78

Group type: COMPARATOR
Intervention: SAD (serenace, ativan, dexamethasone, low dose maxolon)
Number of subjects: 78
Study: 3490329

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 903

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 903
Study: 30244882

Group type: EXPERIMENTAL
Intervention: Dose escalation above 60 Gy EQD2
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Concurrent or sequential chemoradiation or radiation only
Number of subjects: 59
Study: 27041406

Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Follow-up open-label trial with telotristat etiprate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24855132

Group type: EXPERIMENTAL
Intervention: Cervical spine and vestibular rehabilitation (treatment group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard physiotherapy (control group)
Number of subjects: 31
Study: 23315697

Group type: EXPERIMENTAL
Intervention: Energy drink (Megaforce)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (sugar-free lemonade)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 3
Study: 20626608

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg or 50 mg
Number of subjects: 0
Study: 19039629

Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Fluconazole 400 mg
Number of subjects: 106
Study: 16866136

Group type: EXPERIMENTAL
Intervention: Tribendimidine (400 mg)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Albendazole (400 mg)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Tribendimidine (300 mg)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Tribendimidine (400 mg/day for 3 days)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Albendazole (400 mg/day for 3 days)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Tribendimidine (200 mg)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Albendazole (200 mg)
Number of subjects: 368
Study: 12810507

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (untreated plaque)
Number of subjects: 14
Study: 11015484

Group type: EXPERIMENTAL
Intervention: Dietary vitamin A intake (high carotenoid intake)
Number of subjects: 8174

Group type: EXPERIMENTAL
Intervention: Vitamin A intake in infants up to 1 year old
Number of subjects: 8174

Group type: EXPERIMENTAL
Intervention: Vitamin A intake in children ≥3 years of age
Number of subjects: 8174
Study: 8752294

Group type: COMPARATOR
Intervention: Monovalent WC3 reassortant vaccine (serotype G1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quadrivalent WC3 reassortant vaccine (HRV G1, G2, G3, and P[8])
Number of subjects: 0
Study: 1572450

Group type: EXPERIMENTAL
Intervention: Prosthesis with a flowsplitter
Number of subjects: 117

Group type: COMPARATOR
Intervention: Prosthesis with a 90 degrees bifurcation
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study: 3931943

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine infusion (0.1 microgram/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study: 29534765

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service for 2 years
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service for an additional 3 years
Number of subjects: 178

Group type: COMPARATOR
Intervention: Regular care post-2 years of EI
Number of subjects: 178
Study: 29902177

Group type: EXPERIMENTAL
Intervention: Short-term food assistance
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Short-term cash transfers
Number of subjects: 469

Group type: COMPARATOR
Intervention: Standard of care (comparison arm)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 469
Study: 27368012

Group type: EXPERIMENTAL
Intervention: Group A (double-low protocol): 100 kVp tube voltage with 40% ASIR, iodixanol at 270 mg I/mL
Number of subjects: 128

Group type: COMPARATOR
Intervention: Group B: 120 kVp tube voltage with filtered back projection (FBP), iodixanol at 270 mg I/mL
Number of subjects: 128

Group type: COMPARATOR
Intervention: Group C: 120 kVp tube voltage with FBP, ioversol at 350 mg I/mL
Number of subjects: 128
Study: 24179072

Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block (LBBB)
Number of subjects: 1151

Group type: COMPARATOR
Intervention: No new-onset left bundle branch block (LBBB)
Number of subjects: 1151
Study: 22972216

Group type: EXPERIMENTAL
Intervention: Empowerment intervention (10 weekly hour-long sessions including group education and group discussion)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (two-hour education about health management)
Number of subjects: 47
Study: 19073755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2191
Study: 17501758

Group type: EXPERIMENTAL
Intervention: pegIFN plus RBV (1000 mg if body weight <75 kg and 1200 mg if >75 kg)
Number of subjects: 348

Group type: COMPARATOR
Intervention: pegIFN plus RBV (1000-1200 mg/day)
Number of subjects: 348

Group type: COMPARATOR
Intervention: pegIFN plus RBV (800 mg/day)
Number of subjects: 348
Study: 15357755

Group type: EXPERIMENTAL
Intervention: Cryosurgery with liquid nitrogen (single freeze-thaw cycle)
Number of subjects: 90
Study: 11448801

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 69
Study: 9569648

Group type: EXPERIMENTAL
Intervention: Communicators describing traits in others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Associations influencing specific trait impressions of communicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Associative processes in spontaneous trait transference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naturalistic stimuli in Study 4
Number of subjects: 0
Study: 7920074

Group type: EXPERIMENTAL
Intervention: H2-blocker therapy with famotidine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Triple therapy with bismuth, amoxicillin, and metronidazole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Persistent H. pylori infection
Number of subjects: 42

Group type: COMPARATOR
Intervention: No persistent H. pylori infection
Number of subjects: 42
Study: 3289930

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31567725

Group type: EXPERIMENTAL
Intervention: Extended prophylactic nevirapine given daily from 6 weeks to 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall growth (not specified intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short breastfeeding duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimbabwe (location)
Number of subjects: 0
Study: 27513639

Group type: EXPERIMENTAL
Intervention: Periosteal Stimulation Therapy (PST) with boosters and home exercise program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) combined with home exercise program
Number of subjects: 60
Study: 26813525

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF) (25% fat)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Portion control diet (PC) (33% fat)
Number of subjects: 53
Study: 25053182

Group type: EXPERIMENTAL
Intervention: Levosimendan (LS) therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard inotropic therapy
Number of subjects: 94
Study: 22423628

Group type: EXPERIMENTAL
Intervention: Combined strength-training and stretching-exercise group (CSSG, n = 49)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Stretching exercise group (SG, n = 52)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups (CSSG and SG)
Number of subjects: 101
Study: 19535709

Group type: EXPERIMENTAL
Intervention: Standardized multimedia instruction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Personalized video‐assisted oral debriefing
Number of subjects: 30
Study: 18781429

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study: 15215768

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Avoiding high-fat foods intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Increasing fiber intake intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Exercising three times per week intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Identifying pros for weight management
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Self-efficacy for choosing low-fat meals
Number of subjects: 151
Study: 12038920

Group type: EXPERIMENTAL
Intervention: NNT reported in 8 articles
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: ARR reported in 18 articles
Number of subjects: 359
Study: 9642436

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl at 40, 60, or 120 mg bid
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 9402777

Group type: EXPERIMENTAL
Intervention: Experimental trauma centre and regional trauma system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control regions
Number of subjects: 0
Study: 1783533

Group type: EXPERIMENTAL
Intervention: Naloxone (5 mg/kg loading dose over 10 minutes followed by 24-hour infusion at 3.5 mg/kg/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6756362

Group type: EXPERIMENTAL
Intervention: 0.5% diacetyl nadolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% diacetyl nadolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% nadolol
Number of subjects: 0
Study: 30965275

Group type: EXPERIMENTAL
Intervention: 24 weeks of progressive high intensity resistance training, 2 sessions per week, n = 16
Number of subjects: 30

Group type: COMPARATOR
Intervention: 24 weeks of habitual lifestyle, n = 14
Number of subjects: 30
Study: 27808410

Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 5%)
Number of subjects: 993

Group type: COMPARATOR
Intervention: Stable weight (< 5%)
Number of subjects: 993

Group type: COMPARATOR
Intervention: Weight gain (≥ 5%)
Number of subjects: 993
Study: 26091197

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cognitive-Behavior Therapy (CBT)
Number of subjects: 50
Study: 25957143

Group type: EXPERIMENTAL
Intervention: Modified carotid sinus massage (CSM) using ultrasonography
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional carotid sinus massage (CSM)
Number of subjects: 30
Study: 24016810

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (QIV)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Licensed trivalent influenza vaccine (TIV)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Investigational trivalent influenza vaccine (TIV)
Number of subjects: 1116
Study: 22123890

Group type: EXPERIMENTAL
Intervention: MMRV and PCV-7 (group 1)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: PCV-7 followed 6 weeks later by MMRV (group 2)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: MMRV followed 6 weeks later by PCV-7 (group 3)
Number of subjects: 1027
Study: 18264759

Group type: EXPERIMENTAL
Intervention: Letrozole (prolonged treatment beyond 3 months)
Number of subjects: 182
Study: 16368744

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (age- and sex-matched)
Number of subjects: 14
Study: 14730252

Group type: EXPERIMENTAL
Intervention: Clopidogrel in combination with ASA
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Long-term clopidogrel therapy
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Extended clopidogrel therapy
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Clopidogrel > or =6 h before PCI
Number of subjects: 12000
Study: 11072147

Group type: EXPERIMENTAL
Intervention: PTA + BT (intraarterial high-dose-rate brachytherapy)
Number of subjects: 113

Group type: COMPARATOR
Intervention: PTA (percutaneous transluminal angioplasty)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: PTA + BT
Number of subjects: 113

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 113
Study: 9704176

Group type: EXPERIMENTAL
Intervention: Surgery plus postoperative radiotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Radical radiotherapy alone
Number of subjects: 35
Study: 8006845

Group type: EXPERIMENTAL
Intervention: Magnets
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 36

Group type: COMPARATOR
Intervention: Straight bars with clips (control)
Number of subjects: 36
Study: 2805828

Group type: EXPERIMENTAL
Intervention: 4 percent lidocaine (Xylocaine 4 percent topical)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 percent lidocaine (commercial preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 percent preservative-free lidocaine solution
Number of subjects: 20
Study: 766822

Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 31691605

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (10U/kg/leg)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (15U/kg/leg)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (open-label phase)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 31272823

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 3004

Group type: COMPARATOR
Intervention: Intubation
Number of subjects: 3004
Study: 28610668

Group type: EXPERIMENTAL
Intervention: Mepolizumab (detailed dosage not specified)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 711
Study: 27326444

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 23435530

Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc sulfate/Folic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21256803

Group type: EXPERIMENTAL
Intervention: ramelteon 8 mg
Number of subjects: 987

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 987
Study: 19881323

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises with hip internally rotated (n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises with hip externally rotated (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home exercise program with MRFS System (after four weeks of exercises)
Number of subjects: 40